Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
In this study, we analyzed the lymphocyte response to anti-LAG3+anti-PD1 treatment (relatilimab+nivolumab, phase I, NCT01968109) in prior and 4- and 12-week posttherapy blood samples from 40 metastatic melanoma patients using scRNA+TCRαβ-seq, flow cytometry, TCRβ-seq, and serum protein profiling together with ex vivo functional validations.EGA study EGAS00001005580
创建时间：
2023-01-16
